{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:50:59Z","timestamp":1740167459236,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation","doi-asserted-by":"crossref","award":["81971949"],"award-info":[{"award-number":["81971949"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s40121-022-00757-y","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T11:11:20Z","timestamp":1673521880000},"page":"637-647","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effective Analysis of Antiviral Treatment in Patients with HBeAg-Seropositive Chronic Hepatitis B with ALT\u2009<\u20092 Upper Limits of Normal: A Multi-center Retrospective Cohort Study"],"prefix":"10.1007","volume":"12","author":[{"given":"Meixin","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guichan","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sufang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongjie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muye","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuli","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,12]]},"reference":[{"issue":"2","key":"757_CR1","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67(2):370\u201398.","journal-title":"J Hepatol"},{"key":"757_CR2","unstructured":"World Health Organization\u200e. Global hepatitis report 2017. World Health Organization (\u200e2017). https:\/\/apps.who.int\/iris\/handle\/10665\/255016."},{"issue":"3","key":"757_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jhep.2020.09.013","volume":"74","author":"J Howell","year":"2021","unstructured":"Howell J, Pedrana A, Schroeder S, Scott N, Aufegger L, Atun R, et al. A global investment framework for the elimination of hepatitis B. J Hepatol. 2021;74(3):535\u201349.","journal-title":"J Hepatol"},{"issue":"4","key":"757_CR4","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1002\/hep.23424","volume":"51","author":"I Wu","year":"2010","unstructured":"Wu I, Lai C, Han S, Han K, Gordon S, Chao Y, et al. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. Hepatology (Baltimore, MD). 2010;51(4):1185\u20139.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"4","key":"757_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/MCG.0000000000000852","volume":"52","author":"V Wong","year":"2018","unstructured":"Wong V, Hui A, Wong G, Chan R, Chim A, Lo A, et al. Four-year outcomes after cessation of tenofovir in immune-tolerant chronic hepatitis B patients. J Clin Gastroenterol. 2018;52(4):347\u201352.","journal-title":"J Clin Gastroenterol"},{"issue":"32","key":"757_CR6","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.3748\/wjg.v16.i32.4095","volume":"16","author":"G Lv","year":"2010","unstructured":"Lv G, Ma W, Ying L, Jin X, Zheng L, Yang Y. Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels. World J Gastroenterol. 2010;16(32):4095\u20139.","journal-title":"World J Gastroenterol"},{"issue":"12","key":"757_CR7","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.amjmed.2003.12.040","volume":"116","author":"C Chu","year":"2004","unstructured":"Chu C, Hung S, Lin J, Tai D, Liaw Y. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med. 2004;116(12):829\u201334.","journal-title":"Am J Med"},{"issue":"2","key":"757_CR8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s12072-008-9065-2","volume":"2","author":"S Sarin","year":"2008","unstructured":"Sarin S, Kumar M. Should chronic HBV infected patients with normal ALT treated: debate. Hepatol Int. 2008;2(2):179\u201384.","journal-title":"Hepatol Int"},{"key":"757_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.655530","volume":"8","author":"N Liu","year":"2021","unstructured":"Liu N, Yang N, Ma W, Yang S, Hu C, Li J, et al. Efficacy of antiviral treatment in liver biopsy-proven immune-tolerant chronic hepatitis B patients: a retrospective cohort study. Front Med. 2021;8: 655530.","journal-title":"Front Med"},{"key":"757_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104953","volume":"184","author":"Q Zhao","year":"2020","unstructured":"Zhao Q, Liu K, Zhu X, Yan L, Ding Y, Xu Y, et al. Anti-viral effect in chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase. Antiviral Res. 2020;184: 104953.","journal-title":"Antiviral Res"},{"issue":"5","key":"757_CR11","first-page":"655","volume":"9","author":"J Ji","year":"2021","unstructured":"Ji J, Gao J, Wang C, Ouyang L, Liu Z, Liu Z. Characteristics and outcome of exertional heatstroke patients complicated by acute hepatic injury: a cohort study. J Clin Transl Hepatol. 2021;9(5):655\u201360.","journal-title":"J Clin Transl Hepatol"},{"issue":"10","key":"757_CR12","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1016\/j.cgh.2020.04.091","volume":"19","author":"W Jeng","year":"2021","unstructured":"Jeng W, Lok A. Should treatment indications for chronic hepatitis B be expanded? Clin Gastroenterol Hepatol. 2021;19(10):2006\u201314.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"29","key":"757_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000322","volume":"93","author":"W Jia","year":"2014","unstructured":"Jia W, Song L, Fang Y, Wu X, Liu D, Xu C, et al. Antibody to hepatitis B core antigen levels in the natural history of chronic hepatitis B: a prospective observational study. Medicine. 2014;93(29): e322.","journal-title":"Medicine"},{"issue":"12","key":"757_CR14","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.ultrasmedbio.2003.07.001","volume":"29","author":"L Sandrin","year":"2003","unstructured":"Sandrin L, Fourquet B, Hasquenoph J, Yon S, Fournier C, Mal F, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29(12):1705\u201313.","journal-title":"Ultrasound Med Biol"},{"issue":"5","key":"757_CR15","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1053\/j.gastro.2007.08.025","volume":"133","author":"R Gish","year":"2007","unstructured":"Gish R, Lok A, Chang T, de Man R, Gadano A, Sollano J, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology. 2007;133(5):1437\u201344.","journal-title":"Gastroenterology"},{"issue":"1","key":"757_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/jvh.12613","volume":"24","author":"Y Liu","year":"2017","unstructured":"Liu Y, Corsa A, Buti M, Cathcart A, Flaherty J, Miller M, et al. No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg\u2212 patients with chronic hepatitis B after 8 years of treatment. J Viral Hepatitis. 2017;24(1):68\u201374.","journal-title":"J Viral Hepatitis"},{"issue":"3","key":"757_CR17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","volume":"1","author":"H Chan","year":"2016","unstructured":"Chan H, Fung S, Seto W, Chuang W, Chen C, Kim H, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):185\u201395.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"757_CR18","first-page":"850","volume":"9","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Peng H, Liu X, Wang H, Du J, Luo X, et al. Chronic hepatitis B infection with low level viremia correlates with the progression of the liver disease. J Clin Transl Hepatol. 2021;9(6):850\u20139.","journal-title":"J Clin Transl Hepatol"},{"issue":"2","key":"757_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1200\/JCO.2007.13.2043","volume":"26","author":"H Chan","year":"2008","unstructured":"Chan H, Tse C, Mo F, Koh J, Wong V, Wong G, et al. High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol. 2008;26(2):177\u201382.","journal-title":"J Clin Oncol"},{"issue":"1","key":"757_CR20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/liv.13489","volume":"38","author":"N Paik","year":"2018","unstructured":"Paik N, Sinn D, Lee J, Oh I, Kim J, Kang W, et al. Non-invasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with low-level viremia. Liver Int. 2018;38(1):68\u201375.","journal-title":"Liver Int"},{"issue":"10","key":"757_CR21","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/j.1365-2893.2012.01599.x","volume":"19","author":"J Shin","year":"2012","unstructured":"Shin J, Jung S, Park B, Kim C, Eum J, Kim B, et al. Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels. J Viral Hepatitis. 2012;19(10):724\u201331.","journal-title":"J Viral Hepatitis"},{"issue":"12","key":"757_CR22","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.cgh.2007.09.005","volume":"5","author":"H Chan","year":"2007","unstructured":"Chan H, Wong V, Tse A, Tse C, Chim A, Chan H, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol. 2007;5(12):1462\u20138.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"757_CR23","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1038\/s41598-020-58870-2","volume":"10","author":"J Kim","year":"2020","unstructured":"Kim J, Ghosh A, Ayithan N, Romani S, Khanam A, Park J, et al. Circulating serum HBsAg level is a biomarker for HBV-specific T and B cell responses in chronic hepatitis B patients. Sci Rep. 2020;10(1):1835.","journal-title":"Sci Rep"},{"issue":"3","key":"757_CR24","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10238-015-0373-2","volume":"16","author":"S Cai","year":"2016","unstructured":"Cai S, Yu T, Jiang Y, Zhang Y, Lv F, Peng J. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result. Clin Exp Med. 2016;16(3):429\u201336.","journal-title":"Clin Exp Med"},{"issue":"2","key":"757_CR25","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hep.23327","volume":"51","author":"T Chang","year":"2010","unstructured":"Chang T, Lai C, Kew Yoon S, Lee S, Coelho H, Carrilho F, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology (Baltimore, MD). 2010;51(2):422\u201330.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"2","key":"757_CR26","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/hep.23348","volume":"51","author":"Y Chen","year":"2010","unstructured":"Chen Y, Chu C, Liaw Y. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology (Baltimore, MD). 2010;51(2):435\u201344.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"5","key":"757_CR27","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1053\/j.gastro.2010.01.042","volume":"138","author":"J Chen","year":"2010","unstructured":"Chen J, Yang H, Iloeje U, You S, Lu S, Wang L, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology. 2010;138(5):1747\u201354.","journal-title":"Gastroenterology"},{"issue":"3","key":"757_CR28","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.3390\/ijms23031552","volume":"23","author":"M Chang","year":"2022","unstructured":"Chang M, Liaw Y. Hepatitis B flare in hepatitis B e antigen-negative patients: a complicated cascade of innate and adaptive immune responses. Int J Mol Sci. 2022;23(3):1552.","journal-title":"Int J Mol Sci"},{"key":"757_CR29","doi-asserted-by":"publisher","first-page":"3720571","DOI":"10.1155\/2021\/3720571","volume":"2021","author":"X Su","year":"2021","unstructured":"Su X, Chen H, Zhu Z, Xie W, Peng J, Ma X, et al. Clinical diagnostic value of quantitative hepatitis B virus core antibody test in chronic viral hepatitis B. Bioinorg Chem Appl. 2021;2021:3720571.","journal-title":"Bioinorg Chem Appl"},{"issue":"7","key":"757_CR30","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1007\/s10620-019-05489-7","volume":"64","author":"J Kwon","year":"2019","unstructured":"Kwon J, Song M, Jang J, Bae S, Choi J, Yoon S, et al. Efficacy and safety of tenofovir disoproxil fumarate in treatment-na\u00efve patients with chronic hepatitis B in Korea. Dig Dis Sci. 2019;64(7):2039\u201348.","journal-title":"Dig Dis Sci"},{"issue":"5","key":"757_CR31","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00535-016-1270-5","volume":"52","author":"F Suzuki","year":"2017","unstructured":"Suzuki F, Suzuki Y, Hosaka T, Sezaki H, Akuta N, Fujiyama S, et al. Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside\/nucleotide analogs. J Gastroenterol. 2017;52(5):641\u201351.","journal-title":"J Gastroenterol"},{"issue":"7","key":"757_CR32","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/jvh.12679","volume":"24","author":"J Chen","year":"2017","unstructured":"Chen J, Xu C, Xi M, Hu W, Tang Z, Zang G. Predictors of liver histological changes and a sustained virological response to peginterferon among chronic hepatitis B e antigen-positive patients with normal or minimally elevated alanine aminotransferase levels. J Viral Hepatitis. 2017;24(7):573\u20139.","journal-title":"J Viral Hepatitis"},{"issue":"11","key":"757_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080585","volume":"8","author":"H Wang","year":"2013","unstructured":"Wang H, Xue L, Yan R, Zhou Y, Wang M, Cheng M, et al. Comparison of histologic characteristics of Chinese chronic hepatitis B patients with persistently normal or mildly elevated ALT. PLoS ONE. 2013;8(11): e80585.","journal-title":"PLoS ONE"},{"issue":"5","key":"757_CR34","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1136\/gutjnl-2017-314904","volume":"67","author":"GA Kim","year":"2018","unstructured":"Kim GA, Lim YS, Han S, Choi J, Shim JH, Kim KM, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut. 2018;67(5):945\u201352.","journal-title":"Gut"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-022-00757-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-022-00757-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-022-00757-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T03:17:01Z","timestamp":1676344621000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-022-00757-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,12]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["757"],"URL":"https:\/\/doi.org\/10.1007\/s40121-022-00757-y","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"type":"print","value":"2193-8229"},{"type":"electronic","value":"2193-6382"}],"subject":[],"published":{"date-parts":[[2023,1,12]]},"assertion":[{"value":"18 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}